Search Results - "Tetteh, Leticia"

Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer by HAURA, Eric B, TANVETYANON, Tawee, LANXI SONG, RAWAL, Bhupendra, SCHELL, Michael J, BEPLER, Gerold, CHIAPPORI, Alberto, WILLIAMS, Charles, SIMON, George, ANTONIA, Scott, GRAY, Jhanelle, LITSCHAUER, Sharon, TETTEH, Leticia, NEUGER, Anthony

“…Src family kinase (SFK) proteins are frequently activated in cancer and can coordinate tumor cell growth, survival, invasion, and angiogenesis. Given the…”
Get full text

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E -Mutant Melanoma by Eroglu, Zeynep, Chen, Y Ann, Gibney, Geoffrey T, Weber, Jeffrey S, Kudchadkar, Ragini R, Khushalani, Nikhil I, Markowitz, Joseph, Brohl, Andrew S, Tetteh, Leticia F, Ramadan, Howida, Arnone, Gina, Li, Jiannong, Zhao, Xiuhua, Sharma, Ritin, Darville, Lancia N F, Fang, Bin, Smalley, Inna, Messina, Jane L, Koomen, John M, Sondak, Vernon K, Smalley, Keiran S M

“…BRAF inhibitors are clinically active in patients with advanced BRAF -mutant melanoma, although acquired resistance remains common. Preclinical studies…”
Get full text

Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial by Simon, George R, Lush, Richard M, Gump, Jana, Tetteh, Leticia, Williams, Charles, Cantor, Alan, Antonia, Scott, Garrett, Christopher, Rocha-Lima, Caio, Fishman, Mayer, Sullivan, Daniel M, Munster, Pamela N

“…Purpose: Resistance to topoisomerase (topo) I inhibitors has been related to down-regulation of nuclear target enzyme, whereas sensitization to topo II…”
Get full text

High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition by Tarhini, Ahmad A., Eroglu, Zeynep, Galuia, Mariem, Eljilany, Islam, Kalos, Denise, Schell, Michael J, Tetteh, Leticia, Abraham, Edith, Richards, Allison, Brohl, Andrew Scott, Khushalani, Nikhil I., Markowitz, Joseph

“…9543 Background: Options are limited for patients with advanced metastatic melanoma who have disease progression following anti-PD1-based immunotherapy and…”
Get full text

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma by Gibney, Geoffrey T, Kudchadkar, Ragini R, DeConti, Ronald C, Thebeau, Melissa S, Czupryn, Maria P, Tetteh, Leticia, Eysmans, Cabell, Richards, Allison, Schell, Michael J, Fisher, Kate J, Horak, Christine E, Inzunza, H David, Yu, Bin, Martinez, Alberto J, Younos, Ibrahim, Weber, Jeffrey S

“…The anti-programmed death-1 (PD-1) antibody nivolumab (BMS-936558) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was…”
Get full text

Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600‐mutant melanoma by Eroglu, Zeynep, Chen, Y. Ann, Smalley, Inna, Li, Jiannong, Markowitz, Joseph K., Brohl, Andrew S., Tetteh, Leticia, Taylor, Hayley, Sondak, Vernon K., Khushalani, Nikhil I., Smalley, Keiran S. M.

“…Background Resistance to BRAF and MEK inhibitors in BRAF V600‐mutant melanoma is common. Multiple resistance mechanisms involve heat‐shock protein 90 (HSP90)…”
Get full text

Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (HSP90) inhibitor XL888 in advanced BRAFV600 mutant melanoma by Eroglu, Zeynep, Chen, Ann, Li, Jiannong, Markowitz, Joseph, Brohl, Andrew Scott, Tetteh, Leticia, Karpisek, Adam, Taylor, Hayley, Messina, Jane, Sondak, Vernon K., Khushalani, Nikhil I., Smalley, Keiran

“…Abstract only 9553 Background: Resistance to BRAF+MEK inhibitors(i) in BRAF-mutant melanoma is common. Multiple resistance mechanisms involve HSP90 clients,…”
Get full text

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors by GRAY, Jhanelle E, HAURA, Eric, TETTEH, Leticia, AKAR, Angela, XIUHUA ZHAO, SCHELL, Michael J, BEPLER, Gerold, ALTIOK, Soner, CHIAPPORI, Alberto, TANVETYANON, Tawee, WILLIAMS, Charles C, PINDER-SCHENCK, Mary, KISH, Julie A, KREAHLING, Jenny, LUSH, Richard, NEUGER, Anthony

“…Panobinostat, a histone deacetylase (HDAC) inhibitor, enhances antiproliferative activity in non-small cell lung cancer (NSCLC) cell lines when combined with…”
Get full text

Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma by Eroglu, Zeynep, Gibney, Geoffrey Thomas, Weber, Jeffrey S., Kudchadkar, Ragini Reiney, Khushalani, Nikhil I., Markowitz, Joseph, Tetteh, Leticia F., Ramadan, Howida, Zhao, Xiuhua, Chen, Ann, Sharma, Ritin, Messina, Jane, Koomen, John M, Sondak, Vernon K., Smalley, Keiran

“…Abstract only…”
Get full text

Book Review: Madam C. J. Walker’s Gospel of Giving: Black women’s philanthropy during Jim Crow by Freeman. T. M by Tetteh, Leticia Stacey

Get full text

Safety and efficacy of adjuvant anti-PD1 therapy (nivolumab) in combination with vaccine in resected high-risk metastatic melanoma by Gibney, Geoffrey Thomas, Weber, Jeffrey S., Kudchadkar, Ragini Reiney, De Conti, Ronald C., Tetteh, Leticia, Eysmans, Cabell, Yu, Bin, Martinez, Alberto J, Younos, Ibrahim

“…Abstract only 9056^ Background: Nivolumab (BMS-936558), a fully human monoclonal antibody targeting the programmed death-1 (PD-1) receptor, has demonstrated…”
Get full text

The absolute bioavailability of oral vinorelbine in patients with solid tumors by LUSH, Richard M, MCCUNE, Jeannine S, TETTEH, Leticia, THOMPSON, John A, MAHANY, J. J, GARLAND, Linda, SUTTLE, A. Benjamin, SULLIVAN, Daniel M

“…Due to advances in the methods used to quantitate vinorelbine, this study was conducted to characterize fully the bioavailability of an oral dosage form of…”
Get full text